BioPharmCatalyst , a division of Scientist.com, announced that it has expanded the suite of digital tools it provides biotech investors and other life science professionals. The company’s new Elite plan gives users access to BPC’s core services and a wide range of new features, including data on historical probabilities of clinical trial success, insider trading activities, mergers and acquisitions as well as a detailed biotech conference calendar.
“Whether you are an institutional investor, a day trader looking to diversify your portfolio or a healthcare professional keeping tabs on the industry, our advanced biotech investing tools and resources will deliver significant value.”—says Kris Kagan, SVP, BioPharmCatalyst.
BPC now also provides data and analytics on private biotech companies not yet publicly traded. Larger users such as venture capitalists, growth equity investors and private equity investors can access most of this data through BPC’s new Application Programming Interface (API), allowing seamless integration of BPC’s rich data into their existing workflows.
“We’re excited to unveil BioPharmCatalyst Elite in addition to access to our API, which provides our subscriber base with a wealth of new site features and easy access for businesses that want to integrate our data into their everyday processes,” says Kris Kagan, SVP, BioPharmCatalyst. “Whether you are an institutional investor, a day trader looking to diversify your portfolio or a healthcare professional keeping tabs on the industry, our advanced biotech investing tools and resources will deliver significant value.”
BPC provides indispensable tools to anyone interested in investing in the biotech industry. It helps investors make well-informed decisions based on the most recent corporate updates and clinical trial results. The newly released API facilitates real-time data retrieval from various endpoints, such as the FDA calendar, PDUFA calendar, Historical FDA calendar and Company & CEO screener.
SOURCE: PRWewb